Observational studyInternational journal of immunopathology and pharmacology2017
Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.
Open access · hybridAbstract readMulticenter StudyObservational Study
In one paragraph
Observational study in International journal of immunopathology and pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Multidimensional Assessment of Patient-Reported-Outcomes in a Multicenter Cohort of Inborn Errors of Immunity.Journal of clinical immunology · 2026Article
- A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency.Current oncology (Toronto, Ont.) · 2022Article
- Replacement and Immunomodulatory Activities of 20% Subcutaneous Immunoglobulin Treatment: A Single-Center Retrospective Study in Autoimmune Myositis and CVID Patients.Frontiers in immunology · 2021Article
- Long-term efficacy, safety, and tolerability of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin (Ig) (fSCIG; HyQvia(Clinical and experimental medicine · 2020Article
- Patient experience with subcutaneous immunoglobulin 20%, Ig20Gly, for primary immunodeficiency diseases: a prespecified post hoc analysis of combined data from 2 pivotal trials.BMC immunology · 2020Article
- Correlations Among Subcutaneous Immunoglobulin Dosage, Immunoglobulin G Serum Pre-infusional Levels and Body Mass Index in Primary Antibody Deficiency Patients: A Pooled Analysis from the SHIFT/IBIS Studies.Clinical drug investigation · 2020Article
- Heterogeneity of Liver Disease in Common Variable Immunodeficiency Disorders.Frontiers in immunology · 2020Review
- Delivery of subcutaneous immunoglobulin by rapid "push" infusion for primary immunodeficiency patients in Manitoba: a retrospective review.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2020Article
- Pediatric subset of primary immunodeficiency patients treated with SCIG: post hoc analysis of SHIFT and IBIS pooled data.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2020Article
- Intravenous immunoglobulin therapy: a snapshot for the internist.Internal and emergency medicine · 2019Review
- Subcutaneous Immunoglobulin Twenty Percent Every Two Weeks in Pediatric Patients with Primary Immunodeficiencies: Subcohort Analysis of the IBIS Study.Pediatric allergy, immunology, and pulmonology · 2019Article
- Immunosuppressive therapy with rituximab in common variable immunodeficiency.Clinical and molecular allergy : CMA · 2019Review
- Assessment of renal function in patients with myositis and treated with subcutaneous immunoglobulin: a series of 24 cases.Therapeutic advances in musculoskeletal disease · 2018Article
- Potential therapeutic use of IL-37: a key suppressor of innate immunity and allergic immune responses mediated by mast cells.Immunologic research · 2017Review
- Subcutaneous immunoglobulin replacement therapy in a patient with 18q deletion syndrome, primary immune deficiency, and type 1 diabetes.International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 15 institutions in 1 country.
Clementina Canessa1 Anna Meyer Children's Hospital, University of Florence, Florence, Italy.
Jessica Iacopelli1 Anna Meyer Children's Hospital, University of Florence, Florence, Italy.
Antonio Pecoraro2 Department of Translational Medical Sciences, Allergy and Clinical Immunology, University of Naples Federico II, Naples, Italy.
Giuseppe Spadaro2 Department of Translational Medical Sciences, Allergy and Clinical Immunology, University of Naples Federico II, Naples, Italy.
Andrea Matucci3 SOD Immunoallergologia, AOU Careggi, Firenze, Italy.
Cinzia Milito4 Molecular Medicine Department, Sapienza University of Rome, Rome, Italy.
Alessandra Vultaggio3 SOD Immunoallergologia, AOU Careggi, Firenze, Italy.
Carlo Agostini5 Department of Medicine DIMED, Clinical Immunology, Padova University, Padova, Italy.
Francesco Cinetto5 Department of Medicine DIMED, Clinical Immunology, Padova University, Padova, Italy.
Maria Giovanna Danieli6 Clinical Medicine, "Ospedali Riuniti", Ancona, Italy.
Simona Gambini6 Clinical Medicine, "Ospedali Riuniti", Ancona, Italy.
Carolina Marasco7 Department of Biomedical Sciences and Human Oncology, Clinica Medica "G. Baccelli", University of Bari Medical School, Bari, Italy.
Antonino Trizzino8 Department of Pediatric Hematology and Oncology, ARNAS Civico, Palermo, Italy.
Angelo Vacca7 Department of Biomedical Sciences and Human Oncology, Clinica Medica "G. Baccelli", University of Bari Medical School, Bari, Italy.
Domenico De Mattia9 Neonatology and NICU, Department of Biochemical Sciences and Human Oncology, University of Bari, Bari, Italy.
Baldassarre Martire10 Department of Pediatric Science and Surgery, Pediatric Hospital "Policlinico-Giovanni XXIII", Bari, Italy.
Alessandro Plebani11 Department of Clinical and Experimental Sciences, Pediatrics Clinic and Institute for Molecular Medicine A. Nocivelli, University of Brescia, Spedali Civili di Brescia, Brescia, Italy.
Mario Di Gioacchino12 Department of Medicine and Science of Ageing, "G. d'Annunzio" University, Chieti, Italy.
Alessia Gatta12 Department of Medicine and Science of Ageing, "G. d'Annunzio" University, Chieti, Italy.
Andrea Finocchi13 Department of Pediatrics, Unit of Immune and Infectious Diseases, Children's Hospital Bambino Gesù, Rome, Italy.
Francesco Licciardi15 SCDU Pediatria II, Immunoreumatologia, Città della Salute e della Scienza di Torino, Turin, Italy.
Silvana Martino15 SCDU Pediatria II, Immunoreumatologia, Città della Salute e della Scienza di Torino, Turin, Italy.
Marco De Carli16 Dipartimento di Medicina Interna, Azienda Ospedaliera Universitaria Santa Maria della Misericordia, Udine, Italy.
Viviana Moschese17 Department of Pediatrics, "Tor Vergata" University, Policlinico "Tor Vergata", Rome, Italy.
Chiara Azzari1 Anna Meyer Children's Hospital, University of Florence, Florence, Italy.
University of Bari Aldo Moro · ITAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITAzienda Ospedaliero-Universitaria Careggi · ITAzienda Ospedaliero Universitaria Ospedali Riuniti · ITUniversity of Chieti-Pescara · ITUniversity of Florence · ITUniversity of Naples Federico II · ITUniversity of Padua · ITBambino Gesù Children's Hospital · ITMeyer Children's Hospital · ITOspedale Pediatrico Giovanni XXIII · ITOspedale Santa Maria della Misericordia di Udine · ITPoliclinico Tor Vergata · ITSapienza University of Rome · ITUniversity of Brescia · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
In patients with primary antibody deficiencies, subcutaneous administration of IgG (SCIG) replacement is effective, safe, well-tolerated, and can be self-administered at home. A new SCIG replacement at 20% concentration (Hizentra
Indexed as
Administration, IntravenousAdolescentAdultAgedChildFemaleHumansImmunoglobulin GImmunoglobulinsImmunoglobulins, IntravenousImmunologic Deficiency SyndromesInjections, SubcutaneousMaleMiddle AgedYoung AdultHizentraImmunoglobulin GImmunoglobulinsImmunoglobulins, IntravenousVivaglobinimmunoglobulin replacementintravenous immunoglobulinsprimary immunodeficiencysubcutaneous immunoglobulinstherapy satisfaction
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.